title: Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
abstract: Recombinant factor VIIa (NovoSeven; also known as recombinant activated factor VII or eptacog alfa) is structurally similar to human plasma-derived coagulation factor VIIa, but is manufactured using DNA biotechnology. Recombinant factor VIIa interacts with thrombin-activated platelets to produce a thrombin burst leading to accelerated fibrin clot formation localized to the site of vascular injury. It is approved in many countries for use as an intravenous hemostatic agent in patients with congenital hemophilia with inhibitors, and also for acquired hemophilia, factor VII deficiency, and Glanzmann thrombasthenia in some countries. Studies have shown it to be effective and generally well tolerated when used intravenously to treat bleeding episodes or provide hemostatic cover during surgery in patients with congenital hemophilia with inhibitors, acquired hemophilia, factor VII deficiency or Glanzmann thrombasthenia. Based on available data, its efficacy in terms of patient-assessed response may be similar to that of activated prothrombin complex concentrate (aPCC), but treatment with a single 270 microg/kg dose of recombinant factor VIIa might reduce the need for rescue therapy compared with aPCC. Recombinant factor VIIa is not immunogenic in patients with hemophilia, does not produce an anamnestic response in hemophilia patients with inhibitors, and has very low thrombogenicity. It is recommended in guidelines as the treatment of choice for bleeds in patients with hemophilia B with high-responding inhibitors and for patients with factor VII deficiency, and is also a first-line therapeutic option for high-responder hemophilia A patients with inhibitors and those with acquired hemophilia. Cost data from pharmacoeconomic analyses support its use in hemophilia patients with inhibitors. Thus, recombinant factor VIIa is a valuable treatment option for patients with these rare, but potentially serious, bleeding disorders.
authors.affiliation: Wolters Kluwer Health | Adis, Auckland, New Zealand.
authors.forename: Katherine F
authors.initials: KF
authors.lastname: Croom
authors.forename: Paul L
authors.initials: PL
authors.lastname: McCormack
mesh_terms: D001323:Autoantibodies / Q000097:blood*; D001777:Blood Coagulation / Q000187:drug effects*; D025861:Blood Coagulation Disorders, Inherited / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D016063:Blood Loss, Surgical / Q000517:prevention & control; D003029:Coagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000276:immunology / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005168:Factor VII Deficiency / Q000097:blood / Q000188:drug therapy; D015942:Factor VIIa / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000276:immunology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D013915:Thrombasthenia / Q000097:blood / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D003029:Coagulants; D011994:Recombinant Proteins; D015942:Factor VIIa